INCIDENCE, MORTALITY AND SURVIVAL FROM PROSTATE-CANCER IN VAUD AND NEUCHATEL, SWITZERLAND, 1974-1994

Citation
F. Levi et al., INCIDENCE, MORTALITY AND SURVIVAL FROM PROSTATE-CANCER IN VAUD AND NEUCHATEL, SWITZERLAND, 1974-1994, Annals of oncology, 9(1), 1998, pp. 31-35
Citations number
30
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
Journal title
ISSN journal
0923-7534
Volume
9
Issue
1
Year of publication
1998
Pages
31 - 35
Database
ISI
SICI code
0923-7534(1998)9:1<31:IMASFP>2.0.ZU;2-M
Abstract
Backround: Prostate cancer incidence has been increasing in most devel oped countries in the absence of similar trends in mortality, and with variable patterns in different areas of the world. Materials and meth ods. Trends in incidence and mortality from prostate cancer for the pe riod 1974-1994 were analysed using data from the Cancer Registries of the Swiss Cantons of Vaud and Neuchatel. Of 5,010 cases registered, 80 % were histologically or cytologically confirmed. Results. Age-standar dized incidence rates increased from 33.1 to 48.6 per 100,000 (+47%). The upward trends were greater in the most recent calendar periods, an d in the younger age groups (+77% at age 45 to 54; +57% at age 55 to 6 4). in contrast, mortality was stable, with an overall increase of onl y 3% in age-standardized rates (from 20.4 to 21.0 per 100,000), due to some increase in men aged 65 or above. Consequently, the incidence/mo rtality rate ratios increased from 1.6 in 1974-1979 to 2.3 in 1990-199 4. Five-year observed and relative survivals increased from 26% to 41% and from 46% to 58%, respectively. Ten-year observed and relative sur vival for cases diagnosed in 1985-1989 were 19% and 42%, respectively. Survival improvements were greater below age 75. Conclusions. The pat tern of trends in incidence, mortality and survival confirms the influ ence of improved diagnosis of prostate cancer over the last few years in this European population. Still, while Swiss prostatic cancer morta lity rates are the highest in the world (20.3 per 100,000, world stand ard), i.e., about 30% higher than in the United States, all races comb ined, incidence rates are still half as much. On account of the steady increase of prostate-specific antigen testing in Switzerland, further incidence increases are likely.